Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11365232
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 21, 2022
    Assignee: Roche Glycart AG
    Inventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
  • Publication number: 20220168418
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.
    Type: Application
    Filed: November 9, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hélène Cécile HAEGEL, Christian KLEIN, Gabrielle LECLERCQ, Alberto TOSO, Tina ZIMMERMANN
  • Publication number: 20220169748
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • Publication number: 20220159403
    Abstract: A system and a corresponding method for assisting selective hearing are provided. The system includes a detector for detecting an audio source signal portion of one or more audio sources by using at least two received microphone signals of a hearing environment. In addition, the system includes a position determiner for allocating position information to each of the one or more audio sources. In addition, the system includes an audio type classifier for assigning an audio source signal type to the audio source signal portion of each of the one or more audio sources. In addition, the system includes a signal portion modifier for varying the audio source signal portion of at least one audio source of the one or more audio sources depending on the audio signal type of the audio source signal portion of the at least one audio source so as to obtain a modified audio signal portion of the at least one audio source. In addition, the system includes a signal generator.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 19, 2022
    Inventors: Thomas SPORER, Georg FISCHER, Hanna LUKASHEVICH, Florian KLEIN, Stephan WERNER, Annika NEIDHARDT, Ulrike SLOMA, Christian SCHNEIDERWIND, Claudia STIRNAT, Estefania CANO CERON, Jakob ABESSER, Christoph SLADECZEK, Karlheinz BRANDENBURG
  • Patent number: 11334503
    Abstract: An input/output store instruction is handled. A data processing system includes a system nest coupled to at least one input/output bus by an input/output bus controller. The data processing system further includes at least a data processing unit including a core, system firmware and an asynchronous core-nest interface. The data processing unit is coupled to the system nest via an aggregation buffer. The system nest is configured to asynchronously load from and/or store data to at least one external device which is coupled to the at least one input/output bus. The data processing unit is configured to complete the input/output store instruction before an execution of the input/output store instruction in the system nest is completed. The asynchronous core-nest interface includes an input/output status array with multiple input/output status buffers.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: May 17, 2022
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Christoph Raisch, Marco Kraemer, Frank Siegfried Lehnert, Matthias Klein, Jonathan D. Bradbury, Christian Jacobi, Brenton Belmar, Peter Dana Driever
  • Patent number: 11332545
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 17, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Publication number: 20220144963
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: December 22, 2020
    Publication date: May 12, 2022
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11314409
    Abstract: The disclosed technologies address various technical and user experience problems by augmenting the functionality provided by virtual on-screen trackpads without requiring users to switch between modes. In this way, users can access extended functionality without interfering with expected traditional trackpad functionality (e.g. moving a cursor, clicking, and scrolling). In particular, technologies are disclosed for modeless digital pen input to a virtual trackpad, modeless gestures for summoning user interfaces, modeless gestures utilizing position relative to adjacent user interfaces, and modeless cursor control and interaction with virtual touch targets.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: April 26, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Christian Klein, Andrew Stuart Glass
  • Patent number: 11306154
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Patent number: 11294463
    Abstract: The disclosed technologies address various technical problems, including improving human-computer interaction, by augmenting the functionality provided by user input devices using a digital glove. For example, a digital glove can be utilized to provide pressure sensitivity for non-pressure sensitive touchscreen devices, attribute input made with a digital pen to a user wearing the digital glove, augment the functionality provided by mice and other types of handheld user input devices, augment the functionality provided gaze tracking systems, improve camera-based motion tracking systems, and to augment the functionality provided by speech recognition systems.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: April 5, 2022
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Christian Klein, Andrew Stuart Glass, Sang Ho Yoon
  • Publication number: 20220098305
    Abstract: The present invention relates to novel ICOS antibodies and tumor-targeted agonistic ICOS antigen binding molecules comprising them, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 31, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Tanja FAUTI, Jens FISCHER, Lucas HABEGGER, Christian KLEIN, Esther KOENIGSBERGER, Jens NIEWOEHNER, Johannes SAM, Pablo UMAÑA, Joerg ZIELONKA
  • Patent number: 11285207
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • Publication number: 20220088195
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell bispecific antibodies, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using a tyrosine kinase inhibitor such as dasatinib.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 24, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Hélène Cécile Haegel, Alberto Toso, Gabrielle Leclercq, Tina Zimmermann
  • Publication number: 20220072103
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 10, 2022
    Inventors: Laura CODARRI DEAK, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephen Wullschleger
  • Publication number: 20220073646
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 14, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Peter BRUENKER, Christina CLAUS, Claudia FERRARA KOLLER, Sandra GRAU-RICHARDS, Ralf HOSSE, Christian KLEIN, Viktor LEVITSKI, Samuel MOSER, Pablo UMANA
  • Patent number: 11267903
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 8, 2022
    Assignee: Hofmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20220064296
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Publication number: 20220054635
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of adverse effects in response to the administration of a therapeutic agent, particularly a T-cell activating therapeutic agent.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 24, 2022
    Inventors: Marina BACAC, Stefan EVERS, Christian KLEIN, Pavel PISA, Eva ROSSMANN, Jose SARO, Pablo UMANA
  • Publication number: 20220049020
    Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: April 6, 2021
    Publication date: February 17, 2022
    Inventors: Joerg Thomas REGULA, Stefan SEEBER, Wolfgang SCHAEFER, Sabine IMHOF-JUNG, Michael MOLHOJ, Maximiliane KOENIG, Peter BRUENKER, Christian KLEIN
  • Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech